Phase Ib/III study of CAN-017 in patients with esophageal squamous cell cancer (ESCC)

Trial Profile

Phase Ib/III study of CAN-017 in patients with esophageal squamous cell cancer (ESCC)

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs AV 203 (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2017 According to a CANbridge Life Sciences media release, the company has submitted an Investigational New Drug (IND) application to the China Food and Drug Administration (CFDA) for this trial.
    • 02 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top